Program
gemigliptin
Also written as “Gemigliptin”, “Gemigliptin 50mg” and “gemigliptin/metformin HCl extended release”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, led by 2 companies.
Drug pageGemigliptin: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LG Chemits history only | 290 open or running | phase 4since May 24, 2013 | Oct 21, 2009 | none ahead |
| Stendhal Americas | 10 open or running | phase 1since Sep 13, 2017 | Sep 13, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Stendhal Americas only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2017First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT03310749 · 34 enrolled · Mexico
TargetBeta
“An orally bioavailable inhibitor of the serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic and potential renoprotective activities”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sitagliptinrule | Merck | phase 4 | 123 |
| Linagliptinrule | Boehringer Ingelheim | phase 4 | 96 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
The one study Stendhal Americas leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03310749Diabetes Mellitus, Type 2 · Mexico | 1 | Completed | May 3, 2016 | 34 |
How it is read
Names in the registry
- “Gemigliptin”, 7 entries
- “Gemigliptin 50mg”, 5 entries
- “gemigliptin/metformin HCl extended release”, 3 entries
- “gemigliptin and metformin HCl extended release”, 3 entries
- “LC15-0444 50mg qd”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 15 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.